| Ytd | -69.40% | |
| 1y | -59.17% |
| Open | 4.07 | Prev Close | 3.83 | Low | 3.89 | High | 4.08 | Mkt Cap | 9.48M |
| Vol | 75.35K | Avg Vol | 178.07K | EPS | -1.93 | P/E | -2.03 | Forward P/E | -0.52 |
| Beta | 1.40 | Short Ratio | 0.98 | Inst. Own | 11.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 4.99 | 200-d Avg | 9.02 | 1yr Est | 15.75 |
PSTV News
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Pl
The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clini
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — di
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted t
Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial gui
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lo
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare compa
Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and ana
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(1.05) per share which missed the anal
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare compan
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare compan
Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain can
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lo
During the session on Thursday, 461 stocks hit new 52-week lows.